The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous
Names

None

Entity Type

0001425205 Genesis Biopharma, Inc X Corporation

Name of Issuer FREIGHT MANAGEMENT CORP Limited Partnership

Lion Biotechnologies, Inc.

Limited Liability Company

Jurisdiction of
Incorporation/OrganizationGeneral Partnership
Business TrustNEVADAOther (Specify)

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

Lion Biotechnologies, Inc.

Street Address 1 Street Address 2

21900 BURBANK BLVD. THIRD FLOOR

City State/Province/Country ZIP/PostalCode Phone Number of Issuer

WOODLAND HILLS CALIFORNIA 91367 818-992-3126

3. Related Persons

Last Name First Name Middle Name

Singh Manish

Street Address 1 Street Address 2

21900 Burbank Blvd Third Floor

City State/Province/Country ZIP/PostalCode

WOODLAND HILLS CALIFORNIA 91367

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Venkatesan Jay

Street Address 1 Street Address 2

21900 Burbank Blvd Third Floor

City State/Province/Country ZIP/PostalCode

WOODLAND HILLS CALIFORNIA 91367

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Sanford Hillsberg

> **Street Address 1 Street Address 2**

21900 Burbank Blvd Third Floor

State/Province/Country ZIP/PostalCode City

WOODLAND HILLS **CALIFORNIA** 91367

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

McPeak Merrill

> **Street Address 1 Street Address 2**

21900 Burbank Blvd Third Floor

> City State/Province/Country ZIP/PostalCode

WOODLAND HILLS **CALIFORNIA** 91367

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Handelman Michael

> **Street Address 1 Street Address 2**

21900 Burbank Blvd Third Floor

> State/Province/Country ZIP/PostalCode City

WOODLAND HILLS **CALIFORNIA** 91367

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing

Banking & Financial Services X Biotechnology Restaurants Commercial Banking Health Insurance Technology

Insurance Hospitals & Physicians Computers Investing

Pharmaceuticals **Telecommunications Investment Banking**

Pooled Investment Fund Other Health Care Other Technology

Is the issuer registered as Manufacturing Travel

an investment company under Real Estate Airlines & Airports the Investment Company

Commercial

Act of 1940? **Lodging & Conventions** Construction Yes No Tourism & Travel Services

Other Banking & Financial Services **REITS & Finance**

Other Travel **Business Services**

Residential Other Energy

Other Real Estate Coal Mining

Environmental Services

Energy Conservation

Other Energy

Oil & Gas

Electric Utilities

J. ISSUCT SIZC					
Revenue Range	OR	Aggregate Net Asset Value Range			
No Revenues		No Aggregate No	et Asset Value		
\$1 - \$1,000,000		\$1 - \$5,000,000	. 000 000		
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25	,000,000		
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000			
\$25,000,001 - \$100,000,000			\$50,000,001 - \$100,000,000		
Over \$100,000,000		Over \$100,000,0			
X Decline to Disclose		Decline to Disclo	ose		
Not Applicable		Not Applicable			
6. Federal Exemption(s) and Ex	clusion(s) Claim	ned (select all that a	apply)		
		Investment Company Act Section 3(c)			
Rule 504(b)(1) (not (i), (ii)	or (iii))	Section 3(c)	(1) Section 3(c)(9	9)	
Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)		Section 3(c)	(2) Section 3(c)(1	10)	
Rule 504 (b)(1)(iii)		Section 3(c)	(3) Section 3(c)(11)	
Rule 505		Section 3(c)			
X Rule 506(b)		Section 3(c)		•	
Rule 506(c)					
Securities Act Section 4(a)(5)	Section 3(c)		14)	
		Section 3(c)(7)		
7. Type of Filing					
X New Notice Date of First Sa Amendment	ale 2013-11-05	First Sale Yet to	Occur		
8. Duration of Offering					
Does the Issuer intend this offer	ring to last more	e than one year?	Yes X No		
9. Type(s) of Securities Offered	(select all that a	apply)			
X Equity			Pooled Investment Fund	Interests	
Debt		Tenant-in-Common Secu	ırities		
X Option, Warrant or Other Rig	ght to Acquire A	nother Security	Mineral Property Securit	ties	
Security to be Acquired Upo Other Right to Acquire Secu	-	ption, Warrant or	Other (describe)		
10. Business Combination Trans	saction				
Is this offering being made in case a merger, acquisition or exchan		a business combina	tion transaction, such as	Yes X No	
Clarification of Response (if Ne	ecessary):				
11. Minimum Investment					

12. Sales Compensation

Recipient Recipient CRD Number None Roth Capital Partners, LLC 15407

Minimum investment accepted from any outside investor \$10,000 USD

(Associated) Broker or Dealer X None (Associated) Broker or Dealer CRD Number X None None None **Street Address 1 Street Address 2** 888 San Clemente State/Province/Country ZIP/Postal Code City **CALIFORNIA** 92660 Newport Beach State(s) of Solicitation (select all that apply) All States Foreign/non-US Check "All States" or check individual States CALIFORNIA Recipient CRD Number None Recipient Scarsdale Equities LLC 134602 (Associated) Broker or Dealer X None (Associated) Broker or Dealer CRD Number X None None None **Street Address 1 Street Address 2** 10 Rockefeller Plaza Suite 720 ZIP/Postal Code City State/Province/Country New York **NEW YORK** 10020 State(s) of Solicitation (select all that apply) All States Foreign/non-US Check "All States" or check individual States NEW YORK Recipient Recipient CRD Number None American Portfolio Financial Services, Inc. 18487 (Associated) Broker or Dealer CRD Number X None (Associated) Broker or Dealer X None None None **Street Address 1 Street Address 2** 4250 Veterans Memorial Hwy Ste 420E State/Province/Country ZIP/Postal Code City **NEW YORK** 11741 Holbrook State(s) of Solicitation (select all that apply) All States Foreign/non-US Check "All States" or check individual States ARIZONA CALIFORNIA COLORADO CONNECTICUT FLORIDA GEORGIA ILLINOIS INDIANA IOWA KENTUCKY MARYLAND MICHIGAN NEW JERSEY NEW MEXICO

NEW YORK

OHIO OREGON

NORTH CAROLINA

PENNSYLVANIA TENNESSEE Recipient CRD Number None

Agincourt, Ltd. 36661

(Associated) Broker or Dealer X None (Associated) Broker or Dealer CRD Number X None

None None

Street Address 1 Street Address 2

3 Mill Creek Road

City State/Province/Country ZIP/Postal Code

Pembroke BERMUDA HM05

State(s) of Solicitation (select all that apply)
Check "All States" or check individual States

All States X Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount \$23,290,600 USD or Indefinite

Total Amount Sold \$23,290,600 USD

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

117

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$1,478,437 USD Estimate
Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

The Company also issued a total of 726,856 warrants to purchase the Company's common stock at \$2.50 per share.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD X Estimate

Clarification of Response (if Necessary):

Certain proceeds may be used for general working capital purposes which may include compensation and other payments to executive officers listed in Item 3.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

• Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Lion Biotechnologies, Inc.	/s/ Manish Singh	Manish Singh	Chief Executive Officer	2013-11-14

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.